- Home
- ESRT vs PHAT Comparison
ESRT vs PHAT Comparison
Compare ESRT & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ESRT | PHAT |
|---|---|---|
| Founded | 2011 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 942.6M |
| IPO Year | 2013 | 2019 |
Fundamental Metrics
Financial Performance| Metric | ESRT | PHAT |
|---|---|---|
| Price | $6.93 | $14.60 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | $6.80 | ★ $17.33 |
| AVG Volume (30 Days) | ★ 1.2M | 809.7K |
| Earning Date | 10-29-2025 | 10-30-2025 |
| Dividend Yield | ★ 2.02% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.21 | N/A |
| Revenue | ★ $766,184,000.00 | $147,190,000.00 |
| Revenue This Year | $1.95 | $218.59 |
| Revenue Next Year | $2.89 | $84.38 |
| P/E Ratio | $33.83 | ★ N/A |
| Revenue Growth | 1.02 | ★ 460.30 |
| 52 Week Low | $6.55 | $2.21 |
| 52 Week High | $11.29 | $16.45 |
Technical Indicators
Market Signals| Indicator | ESRT | PHAT |
|---|---|---|
| Relative Strength Index (RSI) | 46.81 | 53.40 |
| Support Level | $6.68 | $14.12 |
| Resistance Level | $7.09 | $16.27 |
| Average True Range (ATR) | 0.18 | 0.74 |
| MACD | 0.03 | -0.11 |
| Stochastic Oscillator | 59.37 | 23.18 |
Price Performance
Historical ComparisonAbout ESRT Empire State Realty Trust Inc.
Empire State Realty Trust operates as a pure-play greater New York and Manhattan-focused REIT, featuring its landmark Empire State Building office and observation deck. The company owns and operates around 8.5 million square feet of office space, about 80% of which is located in Manhattan.
About PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.